

Blood Cancer United

Mail Center:

1201 15th Street N.W., Suite 410
Washington, DC 20005
914.949.5213
BloodCancerUnited.org

March 25, 2026

California Institute for Regenerative Medicine (CIRM)
Application Review Subcommittee (ARS)

Re: Support for CLIN2-19191 – TriLeukeVax (TLV) AML Relapse Prevention Trial

Dear Members of the Application Review Subcommittee,

On behalf of Blood Cancer United, we write to express our strong support for the proposed TriLeukeVax (TLV) clinical trial at the University of California, San Francisco.

For patients with acute myeloid leukemia (AML), achieving remission is not the end of their cancer journey—it is the beginning of a period filled with uncertainty. Across California, patients and families live with the constant fear that the disease will return. For many, especially older adults and those not eligible for stem cell transplantation, there are few options specifically designed to keep AML from coming back. Instead, patients are often left in a “watch and wait” phase after remission, without active therapies to prevent relapse at one of the most vulnerable points in their care.

We regularly hear from patients and families facing this reality. One patient shared that after enduring months of intensive treatment to reach remission, the hardest part was going home without a clear plan to keep the leukemia from returning. Each follow-up visit brought anxiety, knowing that relapse could happen at any time and that options would be more limited if it did. This experience is not unique—it reflects a broader gap in care that continues to affect AML patients throughout California.

The proposed TLV study represents a meaningful step toward addressing this unmet need. By helping the immune system recognize and eliminate remaining leukemia cells, this approach is designed to support patients in staying in remission rather than waiting for relapse to occur. Importantly, it offers a potential path forward for patients who cannot tolerate more aggressive treatments and need options that are both accessible and feasible in real-world care settings.

For California patients, advancing this trial is not simply about testing a new therapy—it is about changing what happens after remission. It is about moving from uncertainty to action, and from passive monitoring to proactive care. Supporting this study would help bring forward an approach specifically designed to address one of the most urgent and underserved challenges in AML.

As an organization dedicated to advocating for patients and families affected by blood cancers, we believe it is essential to support research that directly addresses gaps in care and has the potential to improve both outcomes and quality of life.

Blood Cancer United

We respectfully urge the Committee to fund this proposal and support moving this important work forward for patients who need new options now.

Thank you for your consideration and for your continued commitment to patients facing serious and life-threatening diseases.

Sincerely,

Laura Brown

Laura Brown, LMSW
Sr. Director, Patient & Community Outreach
Blood Cancer United